Table 15.7

Immunosuppression Use for Maintenance by Regimen

Two Years Following Transplantation, 1998 to 2002

Recipients with Kidney Transplants

  Transplant Year
1998 1999 2000 2001 2002
Transplants 12,446 12,756 13,611 14,263 14,777
Functioning Graft at 2 Years PostTx 9,962 10,203 11,073 11,837 12,206
With Maintenance Use Recorded at 2 Years PostTx 9,407 9,684 10,838 11,518 11,882
--- + MMF/MPA 0.2% 0.0% 0.0% 0.1% 0.1%
--- + MMF/MPA + Siro/Evero 0.0% 0.0% 0.1% 0.4% 0.5%
--- + MMF/MPA + Steroids 0.7% 1.3% 0.9% 0.9% 0.9%
--- + OtherAntimet 0.0% 0.0% 0.0% 0.0% 0.0%
--- + OtherAntimet + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.0%
--- + OtherAntimet + Steroids 0.1% 0.2% 0.1% 0.1% 0.1%
--- + Siro/Evero 0.1% 0.1% 0.2% 0.3% 0.1%
--- + Siro/Evero + Steroids 0.2% 0.2% 0.4% 0.7% 0.5%
--- + Steroids 0.4% 0.5% 0.5% 0.6% 0.3%
CyA 0.1% 0.6% 0.6% 0.1% 0.1%
CyA + MMF/MPA 0.6% 0.5% 0.9% 1.1% 1.5%
CyA + MMF/MPA + Siro/Evero 0.0% 0.0% 0.2% 0.0% 0.1%
CyA + MMF/MPA + Steroids 26.4% 38.4% 31.0% 24.0% 19.3%
CyA + OtherAntimet 0.2% 0.2% 0.1% 0.0% 0.0%
CyA + OtherAntimet + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.0%
CyA + OtherAntimet + Steroids 3.6% 5.3% 2.9% 1.7% 0.9%
CyA + Siro/Evero 0.0% 0.2% 0.2% 0.1% 0.8%
CyA + Siro/Evero + Steroids 1.6% 1.9% 3.8% 3.3% 2.6%
CyA + Steroids 4.9% 6.6% 4.1% 2.4% 1.6%
Tac 0.3% 0.4% 0.5% 1.1% 1.8%
Tac + MMF/MPA 0.9% 1.5% 1.7% 3.0% 5.8%
Tac + MMF/MPA + Siro/Evero 0.0% 0.0% 0.2% 0.3% 0.5%
Tac + MMF/MPA + Steroids 15.6% 27.4% 30.0% 37.1% 39.5%
Tac + OtherAntimet 0.1% 0.1% 0.2% 0.1% 0.2%
Tac + OtherAntimet + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.0%
Tac + OtherAntimet + Steroids 1.6% 2.2% 1.9% 2.0% 1.6%
Tac + Siro/Evero 0.0% 0.1% 0.7% 1.6% 2.2%
Tac + Siro/Evero + Steroids 0.0% 0.8% 4.3% 6.9% 5.7%
Tac + Steroids 3.9% 5.8% 5.9% 5.6% 5.5%
Other Regimen 38.4% 5.7% 8.4% 6.5% 7.7%


Source: OPTN/SRTR Data as of May 2, 2005.

Percentages are calculated based on the total number of patients with maintenance use at two years following transplantation. They sum to 100 percent for each column.

Transplants prior to year 1998 are not reported due to insufficient reporting of immunosuppressive drug use.

---: No Calcineurin Inhibitor Use; CyA: Cyclosporine; Tac: Tacrolimus.

MMF: Mycophenolate Mofetil; MPA: Mycophenolate Sodium; Siro: Sirolimus; Evero: Everolimus; OtherAntimet: Antimetabolites excluding MMF and MPA.

"Other Regimen" includes drug combinations that are different from the listed regimens and drugs from the text field entering.